JP7578602B2 - Ｐ２ｘ３修飾薬での治療 - Google Patents

Ｐ２ｘ３修飾薬での治療 Download PDF

Info

Publication number
JP7578602B2
JP7578602B2 JP2021549617A JP2021549617A JP7578602B2 JP 7578602 B2 JP7578602 B2 JP 7578602B2 JP 2021549617 A JP2021549617 A JP 2021549617A JP 2021549617 A JP2021549617 A JP 2021549617A JP 7578602 B2 JP7578602 B2 JP 7578602B2
Authority
JP
Japan
Prior art keywords
alkyl
group
hydrogen
compound
endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521955A5 (cg-RX-API-DMAC10.html
JP2022521955A (ja
Inventor
アントニオス・マッゾラニス
デニス・ガルソー
ロベルト・ベリーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 3 Ltd filed Critical GlaxoSmithKline Intellectual Property No 3 Ltd
Publication of JP2022521955A publication Critical patent/JP2022521955A/ja
Publication of JP2022521955A5 publication Critical patent/JP2022521955A5/ja
Application granted granted Critical
Publication of JP7578602B2 publication Critical patent/JP7578602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021549617A 2019-02-25 2020-02-24 Ｐ２ｘ３修飾薬での治療 Active JP7578602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810163P 2019-02-25 2019-02-25
US62/810,163 2019-02-25
PCT/IB2020/000160 WO2020174283A1 (en) 2019-02-25 2020-02-24 Treatment with p2x3 modulators

Publications (3)

Publication Number Publication Date
JP2022521955A JP2022521955A (ja) 2022-04-13
JP2022521955A5 JP2022521955A5 (cg-RX-API-DMAC10.html) 2023-02-24
JP7578602B2 true JP7578602B2 (ja) 2024-11-06

Family

ID=72239247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549617A Active JP7578602B2 (ja) 2019-02-25 2020-02-24 Ｐ２ｘ３修飾薬での治療

Country Status (8)

Country Link
US (1) US12485125B2 (cg-RX-API-DMAC10.html)
EP (1) EP3930722A4 (cg-RX-API-DMAC10.html)
JP (1) JP7578602B2 (cg-RX-API-DMAC10.html)
CN (1) CN113727716A (cg-RX-API-DMAC10.html)
AU (1) AU2020228760A1 (cg-RX-API-DMAC10.html)
CA (1) CA3131312A1 (cg-RX-API-DMAC10.html)
IL (1) IL285772A (cg-RX-API-DMAC10.html)
WO (1) WO2020174283A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3880678T3 (da) 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
JP2023513373A (ja) * 2020-02-14 2023-03-30 べルス・ヘルス・コフ・インコーポレーテッド Ｐ２ｘ３修飾薬
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
GB202212749D0 (en) * 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
JP2013511517A (ja) 2009-11-18 2013-04-04 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール化合物及びその使用
JP2016506935A (ja) 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
JP2017537122A (ja) 2014-12-09 2017-12-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH503559A (de) 1969-02-26 1971-02-28 Arx Paul Von Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP5198256B2 (ja) 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
BR112016003157B1 (pt) 2013-08-15 2021-07-13 Volvo Truck Corporation Método e disposição para balanceamento de um sistema de armazenamento de energia
PE20160431A1 (es) 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
DK3880678T3 (da) * 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
KR102797127B1 (ko) 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
BR112022015818A2 (pt) 2020-02-14 2022-10-25 Bellus Health Cough Inc Preparação de um antagonista de p2x3
JP2023513373A (ja) 2020-02-14 2023-03-30 べルス・ヘルス・コフ・インコーポレーテッド Ｐ２ｘ３修飾薬

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511517A (ja) 2009-11-18 2013-04-04 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール化合物及びその使用
WO2012158117A1 (en) 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
JP2016506935A (ja) 2013-01-31 2016-03-07 ネオメド・インスティチュート イミダゾピリジン化合物及びその使用
JP2017537122A (ja) 2014-12-09 2017-12-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １，３−チアゾール−２−イル置換ベンズアミド
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int. J. Nanomedicine，2017年，vol.12，pp.8171-8183，10.2147/IJN.S146569

Also Published As

Publication number Publication date
CA3131312A1 (en) 2020-09-03
EP3930722A1 (en) 2022-01-05
CN113727716A (zh) 2021-11-30
WO2020174283A1 (en) 2020-09-03
US12485125B2 (en) 2025-12-02
EP3930722A4 (en) 2022-12-28
US20210386751A1 (en) 2021-12-16
IL285772A (en) 2021-10-31
JP2022521955A (ja) 2022-04-13
AU2020228760A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US12485125B2 (en) Treatment with P2X3 modulators
JP7242681B2 (ja) 選択的ｐ２ｘ３修飾薬
US7169797B2 (en) Protein-tyrosine phosphatase inhibitors and uses thereof
US20240299404A1 (en) Treatment of pruritus with p2x3 modulators
WO2009038204A1 (ja) 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
EP2887804B1 (en) Cycloalkanyl[b]indoles useful as glp-1 modulators
EP1908753B1 (en) Novel heterocyclidene acetamide derivative
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
JP2006515587A (ja) 性的不能を治療する方法
EP2040703B1 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
JP2022509206A (ja) Ｍａｇｌ阻害剤による疾病の治療方法
JPWO2010050577A1 (ja) シクロヘキサン誘導体及びその医薬用途
CN115068468B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
US20050136444A1 (en) Treating neuropathic pain with neuropeptide FF receptor 2 agonists
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6903132B2 (en) Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
EP2303264B1 (en) Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives
EP2565184B1 (en) Therapeutic agent and preventative agent for alzheimer's disease
JPH0770013A (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
JP4303474B2 (ja) 医薬活性のある化合物及び使用方法
JPH09208496A (ja) Ｌｈ−ｒｈ拮抗物質含有組成物
HK1258023A1 (zh) 纯5-ht6受体拮抗剂与nmda受体拮抗剂的组合
FR2915100A1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
CS233746B2 (en) Processing of amidazolin derivatives
JP4781362B2 (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240610

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241024

R150 Certificate of patent or registration of utility model

Ref document number: 7578602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150